Corbus Pharmaceuticals Announces Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at 2025 ASCO-GU

Core Insights - Corbus Pharmaceuticals announced the release of an abstract for its first-in-human dose escalation clinical study of CRB-701, which will be presented at the 2025 ASCO GU Symposium [1][2] - The study involves 31 patients as of September 2024, with updated data on 38 patients as of December 2024 to be presented [1] - The three-part Phase 1 Western study is evaluating the safety, pharmacokinetics, and efficacy of CRB-701 in patients with advanced solid tumors expressing high levels of Nectin-4 [3] Company Overview - Corbus Pharmaceuticals is focused on oncology and obesity, with a diverse portfolio aimed at addressing serious illnesses through innovative scientific approaches [5] - The company's pipeline includes CRB-701, an antibody-drug conjugate targeting Nectin-4, CRB-601, an anti-integrin monoclonal antibody, and CRB-913, a CB1 receptor inverse agonist for obesity treatment [5] - Corbus is headquartered in Norwood, Massachusetts, and engages with the public through various social media platforms [5]